Avtor/Urednik		Markovič, Jasmina; Štabuc, Borut
Naslov		The urokinase plasminogen activator and its inhibitors PAI-1 nad PAI-2 in primary cutaneous melanoma
Prevedeni naslov		Urokinazni plazminogenski aktivator in njegova inhibitorja PAI-1 in PAI-2 pri primarnem kožnem melanomu
Tip		članek
Vir		Radiol Oncol
Vol. in št.		Letnik 37, št. 1
Leto izdaje		2003
Obseg		str. 29-35
Jezik		eng
Abstrakt		Background. We investigated the differences in urokinase plasminogen activator (uPA) and its inhibitors type-1 and 2 (PAI-1/2) concentrations in clinically suspected nevi, primary cutaneous melanoma and normal skin and correlations with histopathological prognostic factors of primary melanoma. Patients and methods. Fifty-one patients were enrolled. The tissue concentrations of uPA, PAI 1 and PAI2 were quantified by enzyme-linked immunosorbent assay (ELISA). Results. Mean uPA and PAI-1 concentrations in melanomas were higher than in normal surrounding skin (uPA: 1.08; vs. 0.48 ng/mgp; PAI-1: 14.07 vs. 2.07 ng/mgp; p < 0.001), uPA and PAI-1 concentrations were higher in melanomas than in nevi, and higher in nevi than in normal surrounding skin (uPA: p > 0.05; PAI-1: p = 0.02). PAI-2 concentration was higher in normal surrounding skin than in nevi and melanomas (p > 0.05). Melanoma uPA, PAI-1 and PAI-2 concentrations correlated significantly with normal skin (r= 0.73, 0.54, 0.38 respectively). PAI 1 was significantly lower in melanomas of Breslow thickness < 0.75 mm, Clark invasion of O+I, without microscopic ulceration, without vascular invasion (p < 0.01) than in melanomas of Breslow thickness > 0.75 mm, Clark invasion > II, with ulceration and vascular invasion. Conclusions. Determination of uPA and PAI-1 can provide significant additional prognostic information for melanoma patients.
Izvleček		Izhodišča. Ugotavljali smo razlike v koncentracijah urokinaznega plazminogenskega aktivatorja (uPA) in njegovih inhibitorjev tipa 1 in 2 (PAI-1/2) v klinično sumljivih nevusih, primarnem kožnem melanomu in zdravi koži v okolici ter korelacije s histopatološkimi napovednimi dejavniki primarnega melanoma. Bolniki in metode. Vključili smo 51 bolnikov. Tkivne koncentracije uPA, PAI-1 in PAI-2 smo merili z encimskoimunsko metodo (ELISA). Rezultati. Povprečne koncentracije uPA in PAI-1 v melanomih so bile višje kot v zdravi koži (uPA: 1,08; vs. 0,48 ng/mgp; PAI-1: 14,07 vs. 2,07 ng/mgp; p < 0,001). Koncentracije uPA in PAI1 so bile višje v melanomih kot v nevusih in višje v nevusih kot v zdravi koži (p > 0,05). Koncentracija PAI-2 je bila višja v zdravi koži kot v nevusih in melanomih (p > 0,05). Koncentracije uPA, PAI-1 in PAI-2 v melanomih so statistično značilno korelirale s koncentracijami v zdravi koži (r = 0,73; 0,54; 0,38). Koncentracije PAI-1 so bile statistično značilno nižje v melanomih debeline po Breslowu <_ 0,75 mm, invazije po Clarku O+I, z odsotno mikroskopsko ulceracijo, z odsotno vaskularno invazijo (p < 0,01) kot v melanomih debeline po Breslowu > 0,75 mm, invazije po Clarku > II, s prisotno mikroskopsko ulceracijo, s prisotno vaskularno invazijo. Zaključki. Z določitvijo uPA in PAI-1 lahko dobimo pomemben dodaten podatek o prognozi bolnikov z melanomom.
Deskriptorji		SKIN NEOPLASMS MELANOMA UROKINASE PLASMINOGEN ACTIVATOR INHIBITOR 1 PLASMINOGEN ACTIVATOR INHIBITOR 2 PROGNOSIS